• Je něco špatně v tomto záznamu ?

MicroRNA Profiling of Bone Marrow Plasma Extracellular Vesicles in Multiple Myeloma, Extramedullary Disease, and Plasma Cell Leukemia

J. Gregorova, M. Vlachova, P. Vychytilova-Faltejskova, A. Dostalova, T. Ruzickova, M. Vecera, L. Radova, V. Pospichalova, S. Sladecek, M. Hyzdalova, J. Kotaskova, M. Jarosova, J. Masek, K. Benesova, J. Jarkovsky, L. Rihova, R. Bezdekova, M....

. 2025 ; 43 (1) : e70036. [pub] -

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25010403

Grantová podpora
European union
Fakultni nemocnice Brno
Lékařská fakulta, Masarykova univerzita
Ministerstvo Zdravotnictví Ceské Republiky

Multiple myeloma is a plasma cell malignancy characterized by an abnormal increase in monoclonal immunoglobulins. Despite significant advances in treatment, some patients progress to more aggressive forms of multiple myeloma, including extramedullary disease or plasma cell leukemia. Although the exact molecular mechanisms are not known, several studies have confirmed the involvement of small extracellular vesicle-enriched microRNAs in multiple myeloma progression. Therefore, we performed expression profiling of these molecules in bone marrow plasma of multiple myeloma, extramedullary disease, and plasma cell leukemia patients using small RNA sequencing to identify novel molecules involved in disease pathogenesis. In total, 42 microRNAs were significantly dysregulated among analyzed subgroups. Independent validation by RT-qPCR confirmed elevated levels of miR-140-3p, miR-584-5p, miR-191-5p, and miR-143-3p in multiple myeloma patients compared to extramedullary disease and plasma cell leukemia patients. Subsequent statistical analysis revealed significant correlations between patient clinical characteristics or flow cytometry parameters and microRNA expression. These results indicate that dysregulation of microRNAs could contribute to multiple myeloma progression.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25010403
003      
CZ-PrNML
005      
20250429134628.0
007      
ta
008      
250415s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1002/hon.70036 $2 doi
035    __
$a (PubMed)39804194
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Gregorova, Jana $u Babak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
245    10
$a MicroRNA Profiling of Bone Marrow Plasma Extracellular Vesicles in Multiple Myeloma, Extramedullary Disease, and Plasma Cell Leukemia / $c J. Gregorova, M. Vlachova, P. Vychytilova-Faltejskova, A. Dostalova, T. Ruzickova, M. Vecera, L. Radova, V. Pospichalova, S. Sladecek, M. Hyzdalova, J. Kotaskova, M. Jarosova, J. Masek, K. Benesova, J. Jarkovsky, L. Rihova, R. Bezdekova, M. Almasi, I. Boichuk, M. Stork, L. Pour, S. Sevcikova
520    9_
$a Multiple myeloma is a plasma cell malignancy characterized by an abnormal increase in monoclonal immunoglobulins. Despite significant advances in treatment, some patients progress to more aggressive forms of multiple myeloma, including extramedullary disease or plasma cell leukemia. Although the exact molecular mechanisms are not known, several studies have confirmed the involvement of small extracellular vesicle-enriched microRNAs in multiple myeloma progression. Therefore, we performed expression profiling of these molecules in bone marrow plasma of multiple myeloma, extramedullary disease, and plasma cell leukemia patients using small RNA sequencing to identify novel molecules involved in disease pathogenesis. In total, 42 microRNAs were significantly dysregulated among analyzed subgroups. Independent validation by RT-qPCR confirmed elevated levels of miR-140-3p, miR-584-5p, miR-191-5p, and miR-143-3p in multiple myeloma patients compared to extramedullary disease and plasma cell leukemia patients. Subsequent statistical analysis revealed significant correlations between patient clinical characteristics or flow cytometry parameters and microRNA expression. These results indicate that dysregulation of microRNAs could contribute to multiple myeloma progression.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Vlachova, Monika $u Babak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Vychytilova-Faltejskova, Petra $u Centre for Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic
700    1_
$a Dostalova, Adela $u Babak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Ruzickova, Tereza $u Babak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Vecera, Marek $u Centre for Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000175103694
700    1_
$a Radova, Lenka $u Centre for Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic
700    1_
$a Pospichalova, Vendula $u Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000259572156 $7 mub20201095437
700    1_
$a Sladecek, Stanislava $u Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic
700    1_
$a Hyzdalova, Martina $u Department of Pharmacology and Toxicology, Veterinary Research Institute, Brno, Czech Republic $1 https://orcid.org/0000000302690212
700    1_
$a Kotaskova, Jana $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Jarosova, Marie $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic $1 https://orcid.org/0000000221943433
700    1_
$a Masek, Josef $u Department of Pharmacology and Toxicology, Veterinary Research Institute, Brno, Czech Republic
700    1_
$a Benesova, Klara $u Faculty of Medicine, Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic
700    1_
$a Jarkovsky, Jiri $u Faculty of Medicine, Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic
700    1_
$a Rihova, Lucie $u Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Bezdekova, Renata $u Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Almasi, Martina $u Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Boichuk, Ivanna $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Stork, Martin $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Pour, Ludek $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Sevcikova, Sabina $u Babak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic $1 https://orcid.org/0000000271946771
773    0_
$w MED00002019 $t Hematological oncology $x 1099-1069 $g Roč. 43, č. 1 (2025), s. e70036
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39804194 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429134623 $b ABA008
999    __
$a ok $b bmc $g 2311637 $s 1247484
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 43 $c 1 $d e70036 $e - $i 1099-1069 $m Hematological oncology $n Hematol Oncol $x MED00002019
GRA    __
$p European union
GRA    __
$p Fakultni nemocnice Brno
GRA    __
$p Lékařská fakulta, Masarykova univerzita
GRA    __
$p Ministerstvo Zdravotnictví Ceské Republiky
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Možnosti archivace